Akademik Veri Yönetim Sistemi
3rd International Multidisciplinary Cancer Research Congress , İstanbul, Türkiye, 7 - 10 Eylül 2023, ss.72-73
3rd International Multidisciplinary Cancer Research Congress 7-10 September 2023 Istanbul, Turkiye
Synergistic Anticancer Effects of Auraptene and Tamoxifen on MCF-7 and Ishikawa Cell Cultures in Breast and Endometrial Cancer Cell Lines
Serpil Telci, Sibel Doğan, Seyhun Solakoğlu
Department of Histology and Embryology, Faculty of Medicine, Istanbul University, Istanbul, Turkey
Introduction and Aim: Since breast cancers express high estrogen receptors the use of selective estrogen receptor modulator Tamoxifen is common in the treatment. Tamoxifen increases the risk of endometrial cancer. We planned to examine the possibility of cytotoxicity of the monoterpene coumarin compound Auraptene, which has been shown to have an antiproliferative effect in breast cancer cells, in estrogen dependent endometrial cancer modeling by Ishikawa cells. No study was found in the literature showing the cytotoxicity of Aurapten against Ishikawa cells and endometrial cancer. We studied the potential of Auraptene combined with Tamoxifen in suppressing the endometrial carcinogenesis induced by Tamoxifen and attaining a synergistic effect in breast cancer therapy.
Materials and Methods: Single and combined doses of Auraptene and Tamoxifen were administered to human breast and endometrial cancer cell lines MCF-7 and Ishikawa cell cultures passaged from cell culture laboratory stocks. Cell viability and proliferation were quantified by WST-8 assay with a Multiscan ELISA microreader. Apoptosis assays with the Annexin V/PI staining method and cell cycle tests were analysed with flow cytometry. Cells and nuclear morphology were visualized by laser scanning confocal microscope.
Results: Auraptene elicited cytotoxic effects in Ishikawa and MCF-7 cells by increasing apoptosis and inducing their arrest in the G0/G1 phase of the cell cycle (p<0.001). Tamoxifen incited the proliferation in Ishikawa cells however this stimulation was curbed when combined with Auraptene.
Conclusion: Auraptene can be recommended as a synergistic therapeutic adjuvant in breast cancer to enable Tamoxifen to use more safely by reducing the risk of endometrial cancer and effectively at lower doses.
Keywords: Auraptene, Tamoxifen, breast cancer, flow cytometry, cytotoxicity.